Jun 20, 2018
Aptinyx Announces Pricing of Initial Public Offering
May 17, 2018
Aptinyx Appoints Robert Hombach to Board of Directors
Mar 21, 2018
Aptinyx to Present at Needham & Company's 17th Annual Healthcare Conference
Mar 15, 2018
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Mar 06, 2018
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
Feb 13, 2018
Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
Dec 28, 2017
Aptinyx to Present at 36th Annual J.P. Morgan Healthcare Conference
Dec 18, 2017
Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders
Dec 07, 2017
Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
Dec 07, 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Nov 14, 2017
Aptinyx to Present Preclinical Data for NMDA Receptor Modulators in Neurologic Disorders at Neuroscience 2017
Sep 21, 2017
Aptinyx to Present at Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences
Aug 01, 2017
Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions
Jun 14, 2017
Aptinyx to Present Data for NYX-2925 at the 6th International Congress on Neuropathic Pain